ESMO Breast Cancer Virtual Congress 2021

Analysis of study drug-related interstitial lung disease in patients with HER2+ metastatic breast cancer treated with trastuzumab deruxtecan

Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody Drug Conjugate, for Triple-Negative Breast Cancer: Preliminary Results from an Ongoing Phase 1 Trial